

# Sexually Transmitted Diseases: Hiding in Plain Sight?

Elaine Thomas, MD

Professor, Internal Medicine/Infectious Diseases

University of New Mexico



- A 21 year old woman comes to clinic asking for STD tests. You'll order:
- Depends on how many partners she's had
- Depends on her symptoms
- Urine Gonorrhea/Chlamydia
- Cervix Gonorrhea/Chlamydia
- Throat Gonorrhea/Chlamydia
- Blood for syphilis
- Blood for HIV
- Urine for *Mycoplasma genitalium*
- Herpes antibody test

# STD are increasing! 2018 in US:

1.7 million cases of chlamydia

580,000 gonorrhea

115,000 syphilis

1306 congenital syphilis: 185% increase since 2014

<http://www.cdc.gov/std/stats/default.htm>



# Different Organisms, Similar Diseases

- Chlamydia

- Urethritis
- Cervicitis
- PID
- Epididymitis
- Proctitis, prostatitis?
- Conjunctivitis, trachoma
- Reactive arthritis
- Neonatal pneumonia, conjunctivitis

- Gonorrhea

- Urethritis
- Cervicitis
- PID
- Epididymitis
- Proctitis
- Conjunctivitis
- Pharyngitis
- Disseminated infection
- Neonatal conjunctivitis

**Majority of all infections have no symptoms!**

# Urethritis: Inflammation of the Urethra

## Symptoms/signs:

Urethral discharge

Dysuria

WBC (>5/highpower field)

May progress to epididymitis

## Causes:

Gonorrhea

Chlamydia

Mycoplasma genitalium

Trichomonas


Herpes

Other??






Cervicitis: may have vaginal discharge, bleeding, or no symptoms




Pelvic Inflammatory Disease: abdominal pain, leads to scarring of fallopian tubes

Causes: chlamydia, gonorrhea, maybe other mixed flora, mycoplasmas, etc.



# Complications of Chlamydia and Gonorrhea in Women



Screening and treating for asymptomatic infection is cost-saving!

# Yearly Chlamydia Screen for Any Woman Who:

**Is sexually active and age  $\leq 25$**

**Is sexually active, of any age, and:**

**Has had an STD before OR**

**Has more than one sexual partner OR**

**Does not use condoms consistently and correctly**

**Guideline endorsed by CDC, AMA, American Acad. of  
USPS Task Force, ACOG, etc.**


**Proven to reduce PID** (NEJM 334:1362, 1996)

**Less than half of eligible women get screened!**





# Nucleic-acid Amplification Tests for Gonorrhea and Chlamydia



- Very sensitive
- Urine, urethral, cervical, vaginal, anal, pharyngeal
  - Triple screen for MSM
- Can screen asymptomatic males
- Can use in non-clinical settings
- Can self-collect
- DOESN'T test for resistance
- Know what kind of test your lab offers

Extragenital sites in women: [Sex Transm Dis.](#) 42:233, 2015

Self-collection: [Sex.Transm.Dis.](#) 38:1107, 2011; [Sex.Transm.Dis.](#) 36:493, 2009

# Chlamydia Treatment: CDC 2015 guidelines

## Recommended regimens:


- Azithromycin 1 g PO x 1 (watch for vomiting)
- Doxycycline 100 mg PO BID x 7 d (watch for nonadherence)

## Alternatives:

- Erythromycin base 500 mg PO QID x 7 d
  - Erythromycin ethylsuccinate 800 mg PO QID x 7 d
  - Ofloxacin 300 mg PO BID x 7 d
  - Levofloxacin 500 mg PO QD x 7 d
- 
- Good review of concerns about equivalence of doxy and azithro:  
Dombrowski et al., Sex Transm Dis 43: 603, 10/2016

# Gonorrhea: evolution of resistance

Has acquired multiple plasmid and chromosomal resistance mutations



Now rare reports of gonorrhea resistant to all antibiotics usually used!

Adapted from Workowski et al., Ann.Int.Med 2008, 148(8):606

Gonorrhea Treatment: [www.cdc.gov/std/gonorrhea/](http://www.cdc.gov/std/gonorrhea/)

**Uncomplicated gonorrhea of cervix, urethra, or rectum**

Ceftriaxone 250 mg IM once *PLUS*

Azithromycin or doxycycline as for chlamydia  
(EVEN if chlamydia test negative)

***Alternative regimens: ONLY IF ceftriaxone not available:***

Cefixime 400 mg single oral dose *PLUS*

Azithromycin or doxycycline as for chlamydia  
*PLUS* Test of cure in 1 week

**Serious cephalosporin allergy:**

Consult expert, and test of cure

# Gonorrhea and Chlamydia: Re-testing after treatment

---

- Test of cure not needed unless pregnant or second-line tx
- Nucleic acid amplification tests positive up to 2 weeks after treatment (CID 62:1348, 2016)
- Re-infection rate
  - Chlamydia - women 7-25%; men 13%;
  - Gonorrhea - women: 12-24%; men 9%
- Retesting recommendation (CDC)
  - Women: retest 3 mo after treatment, or at next visit within 12 mo
  - Less evidence for men (suggest retest in 3 mo)




- A young man who has had sex with multiple men comes in with urethral burning and a scant penile discharge. You treat him with azithromycin. His tests come back negative for GC and CT. He comes back a month later. His symptoms got a little better but then came back.

## *Mycoplasma genitalium*: uncertain significance!

- Organism associated with urethritis, cervicitis, PID, preterm birth, infertility, HIV transmission
- But LESS strongly than CT and GC, so causative role uncertain
- New nucleic amplification test recently approved
- Screening NOT currently recommended
- Consider testing symptomatic cases, especially if failing treatment
- Poor response to doxycycline; increasing resistance to azithromycin
  - Moxifloxacin? - though some resistance reported


# Primary and Secondary Syphilis: Rates of Reported Cases by County, 2018



\* Per 100,000.

<sup>†</sup> In 2018, 1,498 (47.7%) of 3,142 counties in the United States reported no cases of primary and secondary syphilis. See section A1.4 in the Appendix for more information on county-level rates.

# Primary and Secondary Syphilis — Rates of Reported Cases by Sex and Male-to-Female Rate Ratios, United States, 1990–2018



\* Per 100,000.

† Log scale.

# Why isn't Syphilis gone?

- Easy to treat – no antibiotic resistance
- Targets people with less access to health care
- Can't be seen on Gram stain or grown in the lab
- Long periods with no symptoms, yet causes serious disease
- Diagnosis depends on serology (blood antibody) tests with many pitfalls in interpretation



# Syphilis Serology

- Traditionally: nontreponemal first, if positive confirm with treponemal
- Some labs now do a new treponemal Ab first

Nontreponemal	Treponemal
RPR, VDRL	TPPA, MHA-TP, FTA, new Trep-Sure
Quantitative	Qualitative
Titers go down with treatment – Can be negative in early or late disease	Stays + for life, with or w/o treatment
False positives and negatives	More specific

**Table 2. Sensitivity and Specificity of Treponemal Assays for Detection of Syphilis, by Stage and Overall**

Assay	Sensitivity by Stage				Overall Sensitivity (n = 262)	Overall Specificity (n = 403)
	Primary (n = 55)	Secondary (n = 98)	Early Latent (n = 41)	Late Latent (n = 68)		
FTA-ABS	<b>78.2<sup>a</sup></b> (65.0–88.2)	<b>92.8<sup>a</sup></b> (85.7–97.0)	100 (90.7–100)	92.6 (83.7–97.6)	<b>90.8<sup>a</sup></b> (86.7–94.0)	98.0 (96.1–99.1)
TPPA	94.5 (84.9–98.9)	100 (96.2–100)	100 (90.7–100)	<b>86.8<sup>b</sup></b> (76.4–93.8)	95.4 (92.1–97.6)	100 (99.0–100)
Centaur CIA	94.5 (84.9–98.9)	100 (96.2–100)	100 (90.7–100)	94.1 (85.6–98.4)	97.3 (94.6–98.9)	95.5 (93.0–97.3)
Trep-Sure EIA	94.5 (84.9–98.9)	100 (96.2–100)	100 (90.7–100)	98.5 (92.1–99.9)	98.5 (96.1–99.6)	<b>82.6<sup>c</sup></b> (78.4–86.1)
LIAISON CIA	96.4 (94.5–98.2)	100 (96.2–100)	97.6 (87.4–99.9)	92.6 (83.7–97.6)	96.9 (94.1–98.7)	94.5 (91.8–96.5)
Bioplex MBIA	96.4 (94.5–98.2)	100 (96.2–100)	95.1 (83.8–99.4)	94.1 (85.6–98.4)	96.9 (94.1–98.7)	96.7 (94.4–98.2)
INNO-LIA	96.4 (94.5–98.2)	100 (96.2–100)	100 (90.7–100)	91.1 (81.7–96.7)	96.9 (94.1–98.7)	98.5 (96.8–99.5)

Data are presented as % (95% confidence interval).

Abbreviations: CIA, chemiluminescence immunoassay; EIA, enzyme immunoassay; FTA-ABS, fluorescent treponemal antibody absorption test; LIA, line immunoassay; MBIA, microbead immunoassay; TPPA, *Treponema pallidum* particle agglutination assay.

<sup>a</sup>FTA-ABS was less sensitive than other assays for primary syphilis (all  $P \leq .01$ ) and secondary syphilis ( $P = .007$ ). Combining all stages, FTA-ABS was less sensitive than TPPA ( $P = .038$ ) or the immunoassays (all  $P < .001$ ).

<sup>b</sup>TPPA significantly less sensitive than Trep-Sure EIA for late latent syphilis ( $P = .009$ ); all other comparisons were not statistically significant.

<sup>c</sup>Trep-Sure EIA was significantly less specific than all other assays (all  $P < .001$ ).

# Syphilis: Primary Chancre



Images from: *STD Atlas, 1997*



# Rash of Secondary Syphilis – can look like anything!!



# Secondary Syphilis: Other clues

Patchy alopecia



Condyloma lata

Mucous patches





# Determining syphilis stage is critical for management

## Incubating syphilis

Recent exposure, may be infected; blood test may not be positive yet

Primary: 3-6 weeks after infection - Chancre, localized lymphadenopathy

Secondary: 6-12 weeks after infection

Rash, lymphadenopathy, fever, mucous patches, alopecia, headache, hepatitis, nephritis, etc.!

## Early Latent

No signs and symptoms, < 1 year after infection

Can still be infectious; secondary signs may recur

**TX: LA Bicillin x 1**

---

## Late Latent

No signs and symptoms, > 1 year after infection

Less infectious, symptoms probably will not recur

## Latent unknown duration

Positive serology, no signs/symptoms, unknown time of infection

**TX: LA Bicillin x 3**

Tertiary Syphilis – years later: neurological, cardiovascular, gummatous lesions

---

## Neurosyphilis

Can happen at ANY stage

Eye or ear disease - treat same as neurosyphilis


**TX: IV penicillin 14 days**




# Syphilis in Pregnancy

- Screen ALL pregnant
- Transmission more common in 2nd & 3rd trimester
- Treatment effective if completed in time
- Outcome in untreated early syphilis
  - 25% intrauterine death
  - 25% perinatal death
  - 50% congenital syphilis
- How does congenital syphilis happen?:
  - No prenatal care
  - Incomplete, late, or interrupted care
  - Misinterpretation or miscommunication of tests
  - Woman infected after testing
  - Wrong, too-late or incomplete treatment





CONGENITAL SYPHILIS.



Many Bad  
Outcomes –  
Early and Late

# Testing in Pregnancy

- All women must be tested at first prenatal visit
- Either treponemal or nontreponemal screen
- False positives do happen, need careful evaluation
- “High-risk” women or those in “high-risk area” should be tested again in 3<sup>rd</sup> trimester and at delivery
- No newborn should leave hospital without maternal tests known

# Syphilis Management: CDC Guideline

- Careful history and exam, including neurologic, eye
- Treat according to disease stage
- Followup RPR at 3, 6, 12 months to look for 4-fold drop
- Penicillin allergy? Take a good history; many are not truly allergic
- Doxycycline alternative if PCN-allergic, except:
- Pregnancy or neurosyphilis – ONLY penicillin; get expert advice!
- Pregnancy: RPR monthly till delivery; coordinate with OB and Pediatrics
- Help from Health Department to ensure partners treated




# Herpes Simplex

- Type 1 *usually* oral, Type 2 *usually* genital
- US adult HSV-2 Seroprevalence (NHANES): 17%
- Most who have it don't know it
- Can be transmitted by asymptomatic shedding
- Can seriously infect neonates – skin, CNS, or disseminated (rare)
- Acyclovir, valacyclovir, famciclovir:
  - episodically for outbreaks or
  - daily for suppression



# Trichomonas (a CDC “neglected parasite”)

- Prevalence: ~3% in women 14-49 yo; older age range than gonorrhea and chlamydia
- Many asymptomatic
- Associated with:
  - postpartum endometritis, low birth weight, preterm labor, PROM
  - HIV transmission/acquisition
- Metronidazole resistance increasing though still uncommon
  - Higher dose metronidazole or tinidazole may cure
- No great options for true metronidazole allergy – consider desensitization
- Metronidazole-alcohol interaction is probably rare
- 500 mg BID x 7 days better than 2 gm x 1
- Topical metronidazole less effective
- Must treat the partner(s)!
- Diagnosis in men has been a barrier; Tricore Lab can do on urine



# Human Papilloma Virus and Genital Warts


- Very common; mostly asymptomatic
- Some strains mostly warts, others cause dysplasia/cancer
- Infection, and warts, may spontaneously resolve
- Worse in immunocompromised
- Vaccine is very effective and safe!



Elaine Thomas, MD



## CIN 2 and 3 (cervical dysplasia): Prevalence/1000 Person-Years, Females in Private Health Plans, 2007–2014



**SOURCE:** Flagg EW, Torrone EA, Weinstock H. Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007–2014. *Am J Public Health* 2016; 106(12):2211–2218.

# Principles of STI Management

- Follow CDC treatment guidelines
  - [www.cdc.gov/std/treatment/default.htm](http://www.cdc.gov/std/treatment/default.htm)
- Test patient for other STI, **including HIV**
- Notify Public Health Department (reportable diseases)
- Evaluate and treat all recent partners
- Educate patient: treatment failure, prevention, rescreening
- Condoms reduce risk
- Discuss HIV PrEP if at risk

# What will you do differently as a result of this talk?

- Screen more young people routinely for GC/CT?
- Check what kind of GC/CT test your facility uses? Throat/rectal?
- Test for syphilis and HIV too?
- Check whether your lab uses treponemal or nontreponemal test?
- Ask patients more about their sexual history?
- Find out where people can get PrEP in your area?
- Re-test patients 3 months after a GC or CT diagnosis?
- Re-test pregnant women in 3<sup>rd</sup> trimester and at delivery?
- Education/outreach about STD to your community?

# Resources and Reading

CDC STD 2015 Treatment Guideline: [www.cdc.gov/std/treatment/default.htm](http://www.cdc.gov/std/treatment/default.htm)

STD Prevention Training Centers - resources and online self-study,

for example: <http://californiaptc.com/online-learning/> and <https://www.std.uw.edu/>

CDC self-study: <http://www.cdc.gov/std/training/std101/home.htm>

USPS Task Force: <https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-recommendations-for-sti-screening>

New Mexico Expedited Partner Therapy guideline: <https://nmhealth.org/publication/view/help/1602/>

Herpes review: Gupta et al., Lancet 370:2127, 2007

Chlamydia review: Weisenfeld HC, N Engl J Med 2017;376:765

[Lutz AR, LGBT Health.](#) 2015;2:27. Screening for Asymptomatic Extragenital Gonorrhea and Chlamydia in Men Who Have Sex with Men: Significance, Recommendations, and Options for Overcoming Barriers to Testing.

California STD/HIV Screening Recommendations in Pregnancy 2017:

<https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CaliforniaSTD-Sxand-Tx-inPregnancy2017.pdf>

JAMA, “Why are mothers still passing syphilis to their babies?” <https://jamanetwork.com/journals/jama/article-abstract/2724373>